tiprankstipranks
Cell Source Inc (CLCS)
OTHER OTC:CLCS
US Market

Cell Source (CLCS) Price & Analysis

11 Followers

CLCS Stock Chart & Stats

$0.93
>-$0.01(-0.30%)
At close: 4:00 PM EST
$0.93
>-$0.01(-0.30%)

CLCS FAQ

What was Cell Source Inc’s price range in the past 12 months?
Cell Source Inc lowest stock price was $0.27 and its highest was $2.25 in the past 12 months.
    What is Cell Source Inc’s market cap?
    Cell Source Inc’s market cap is $50.96M.
      When is Cell Source Inc’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Cell Source Inc’s earnings last quarter?
      Currently, no data Available
      Is Cell Source Inc overvalued?
      According to Wall Street analysts Cell Source Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Cell Source Inc pay dividends?
        Cell Source Inc does not currently pay dividends.
        What is Cell Source Inc’s EPS estimate?
        Cell Source Inc’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Cell Source Inc have?
        Cell Source Inc has 67,945,854 shares outstanding.
          What happened to Cell Source Inc’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Cell Source Inc?
          Currently, no hedge funds are holding shares in CLCS
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Company Description

            Cell Source Inc

            Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
            Similar Stocks
            Company
            Price & Change
            Follow
            Bioline RX Ltd Sponsored ADR
            Can-Fite BioPharma
            Soligenix
            Longeveron
            Popular Stocks